Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand
Chloroquine-resistant Plasmodium vivax malaria has been reported in several geographical areas. The P. vivax life-cycle includes dormant hepatic parasites (hypnozoites) that cause relapsing malaria weeks to years after initial infection. Curative therapy must therefore target both the erythrocytic a...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/25463 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.25463 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.254632018-09-07T16:01:03Z Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand S. Looareesuwan P. Wilairatana R. Glanarongran K. A. Indravijit L. Supeeranontha S. Chinnapha T. R. Scott J. D. Chulay Mahidol University Glaxo Wellcome (Thailand) Ltd. GlaxoSmithKline, USA Immunology and Microbiology Medicine Chloroquine-resistant Plasmodium vivax malaria has been reported in several geographical areas. The P. vivax life-cycle includes dormant hepatic parasites (hypnozoites) that cause relapsing malaria weeks to years after initial infection. Curative therapy must therefore target both the erythrocytic and hepatic stages of infection. Between July 1997 and June 1998, we conducted an open-label study in Thailand to evaluate the efficacy and tolerability of a sequential regimen of combination atovaquone (1000 mg) and proguanil hydrochloride (400 mg), once daily for 3 days, followed by primaquine (30 mg daily for 14 days) for treatment of vivax malaria. All 46 patients who completed the 3-day course of atovaquone-proguanil cleared their parasitaemia within 2-6 days. During a 12-week follow-up period in 35 patients, recurrent parasitaemia occurred in 2. Both recurrent episodes occurred 8 weeks after the start of therapy, consistent with relapse from persistent hypnozoites rather than recrudescence of persistent blood-stage parasites. The dosing regimen was well tolerated. Results of this trial indicate that atovaquone-proguanil followed by primaquine is safe and effective for treatment of vivax malaria. 2018-09-07T08:51:38Z 2018-09-07T08:51:38Z 1999-01-01 Article Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.93, No.6 (1999), 637-640 10.1016/S0035-9203(99)90079-2 00359203 2-s2.0-0033397071 https://repository.li.mahidol.ac.th/handle/123456789/25463 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033397071&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Immunology and Microbiology Medicine |
spellingShingle |
Immunology and Microbiology Medicine S. Looareesuwan P. Wilairatana R. Glanarongran K. A. Indravijit L. Supeeranontha S. Chinnapha T. R. Scott J. D. Chulay Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
description |
Chloroquine-resistant Plasmodium vivax malaria has been reported in several geographical areas. The P. vivax life-cycle includes dormant hepatic parasites (hypnozoites) that cause relapsing malaria weeks to years after initial infection. Curative therapy must therefore target both the erythrocytic and hepatic stages of infection. Between July 1997 and June 1998, we conducted an open-label study in Thailand to evaluate the efficacy and tolerability of a sequential regimen of combination atovaquone (1000 mg) and proguanil hydrochloride (400 mg), once daily for 3 days, followed by primaquine (30 mg daily for 14 days) for treatment of vivax malaria. All 46 patients who completed the 3-day course of atovaquone-proguanil cleared their parasitaemia within 2-6 days. During a 12-week follow-up period in 35 patients, recurrent parasitaemia occurred in 2. Both recurrent episodes occurred 8 weeks after the start of therapy, consistent with relapse from persistent hypnozoites rather than recrudescence of persistent blood-stage parasites. The dosing regimen was well tolerated. Results of this trial indicate that atovaquone-proguanil followed by primaquine is safe and effective for treatment of vivax malaria. |
author2 |
Mahidol University |
author_facet |
Mahidol University S. Looareesuwan P. Wilairatana R. Glanarongran K. A. Indravijit L. Supeeranontha S. Chinnapha T. R. Scott J. D. Chulay |
format |
Article |
author |
S. Looareesuwan P. Wilairatana R. Glanarongran K. A. Indravijit L. Supeeranontha S. Chinnapha T. R. Scott J. D. Chulay |
author_sort |
S. Looareesuwan |
title |
Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
title_short |
Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
title_full |
Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
title_fullStr |
Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
title_full_unstemmed |
Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
title_sort |
atovaquone and proguanil hydrochloride followed by primaquine for treatment of plasmodium vivax malaria in thailand |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/25463 |
_version_ |
1763488748760203264 |